EPHA2 and neoplasm: Additionally, the combination of EphA2 inhibitors with histone deacetylase inhibitors has been shown to downregulate survival pathways and reduce tumor burden, highlighting the promise of multitargeted approaches in endometrial cancer treatment (18, 46).